

## **Amendments to the Claims**

### **Listing of the Claims:**

This Listing of the Claims will replace all prior versions, and listings of the claims in the application.

1-124 (Cancelled).


125. (Presently Amended): A hapten-carrier conjugate comprising

at least one hapten ~~derived from nicotine, wherein the hapten is nicotine~~ which is nicotine, a nicotine derivative or a salt thereof; and

at least one carrier which is a bacterial toxin ~~containing a T-cell epitope~~ and

wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 1.1	CO <sub>2</sub> Q
CJ 1.2	COQ
CJ 1.3	OCH <sub>3</sub>
CJ 2	OCO(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 2.1	OCOCH=Q
CJ 2.2	OCOCH(O)CH <sub>2</sub>
CJ 2.3	OCO(CH <sub>2</sub> ) <sub>n</sub> CH(O)CH <sub>2</sub>
CJ 3	CO(CH <sub>2</sub> ) <sub>n</sub> COQ
CJ 3.1	CO(CH <sub>2</sub> ) <sub>n</sub> CNQ
CJ 4	OCO(CH <sub>2</sub> ) <sub>n</sub> COQ
CJ 4.1	OCO(CH <sub>2</sub> ) <sub>n</sub> CNQ
CJ 5	CH <sub>2</sub> OCO(CH <sub>2</sub> ) <sub>n</sub> COQ
CJ 5.1	CH <sub>2</sub> OCO(CH <sub>2</sub> ) <sub>n</sub> CNQ
CJ 6	CONH(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 7	Y(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 7.1	CH <sub>2</sub> Y(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 8	OCOCH(OH)CH <sub>2</sub> Q
CJ 8.1	OCO(CH <sub>2</sub> ) <sub>n</sub> CH(OH)CH <sub>2</sub> Q
CJ 9	OCOC <sub>6</sub> H <sub>5</sub>
CJ 10	<u>as identified in the application as FIG. 2b</u>



, wherein Q' is a modified

protein;

CJ 11

YCO(CH<sub>2</sub>)<sub>n</sub>COQ

and wherein for each branch, n is independently an integer; Y is S, O, or NH; and Q is the carrier. is selected from the group consisting of: a protein or peptide carrier, modified protein or peptide carrier, or another branch identified by its "CJ" reference number..

126. (Previously Presented): The hapten-carrier conjugate of claim 125, wherein n is from 3 to 20.

127. (Cancelled).

128. (Previously Presented): The hapten-carrier conjugate of claim 125, wherein greater than one hapten is coupled to the carrier.

129. (Presently Amended): The hapten-carrier conjugate of claim 125, wherein the carrier is ~~cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus like particle.~~

130. (Cancelled).

131. (Previously Presented): A pharmaceutical preparation comprising the hapten-carrier conjugate of claim 125, and a pharmaceutically acceptable excipient.

132. (Previously Presented): The pharmaceutical preparation of claim 131, further comprising an adjuvant.

133. (Previously Presented): The pharmaceutical preparation of claim 132, wherein the adjuvant is alum or RIBI adjuvant.

134. (Previously Presented): The pharmaceutical preparation of claim 133, wherein the adjuvant is alum.

135. (Previously Presented): The pharmaceutical preparation of claim 134, wherein the alum is aluminum hydroxide or aluminum phosphate.

136. (Previously Presented): The pharmaceutical preparation of claim 131, further comprising an auxiliary agent or supplementary active compound.

137. (Previously Presented): The pharmaceutical preparation of claim 131 which is suitable for parenteral administration to a human.

138. (Previously Presented): The pharmaceutical preparation of claim 131 which is suitable for oral, dermal or topical administration to a human.

139. (Previously Presented): A pharmaceutical preparation comprising the hapten-carrier conjugate of claim 130, and a pharmaceutically acceptable excipient.

140. (Previously Presented): The pharmaceutical preparation of claim 139 further comprising an adjuvant.